Dasatinib (Sprycel) for CML and Ph+ ALL

Medical Letter on Drugs and Therapeutics

Volumn 49, Issue 1252, 2007, Pages 6-7

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; DASATINIB; IMATINIB; PROTON PUMP INHIBITOR; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DIARRHEA; DRUG EXCRETION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PANNICULITIS; QT PROLONGATION; SHORT SURVEY; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; DRUG INTERACTION;

CLINICAL TRIALS; DRUG INTERACTIONS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; LEUKEMIA, MYELOID, CHRONIC; MULTICENTER STUDIES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; TREATMENT OUTCOME;

EID: 33846912549     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (12)

1. Gleevec (STI-571) for chronic myeloid leukemia. Med Lett Drugs Ther 2001; 43:49.
2. BJ Druker et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408.
3. HM Kantarjian et al. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006; 145:913.
4. A Hochhaus et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2006 Nov 30; epub.
5. M Talpaz et al. Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 'START-A' study. J Clin Oncol 2006; 24 suppl:343s, abstract 6526.
6. J Cortes et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2006 Dec 21; epub.
7. S Coutre et al. Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are imatinib 9IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 'START-L' study. J Clin Oncol 2006; 24 suppl:344s, abstract 6528.
8. NP Shah et al. Dasatinib (D) vs high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial. J Clin Oncol 2006; 24 suppl:338s, abstract 6507.
9. S Assouline et al. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med 2006; 354:2623.
10. R Kerkela et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12:908.
11. CYP3A and drug interactions. Med Lett Drugs Ther 2005; 47:54
12. Based on the most recent data (November 30, 2006) from retail pharmacies nationwide available from Wolters Kluwer Health.